Company
Gedeon Richter
Gedeon Richter has 15 drugs tracked on RxWires: 2 post-market, 2 in Phase 3, 5 in Phase 2, 6 in Phase 1.
Pipeline
| Drug | Phase | Indication |
|---|---|---|
| Myo-inositol | Post-Market | Ovulation Induction |
| spironolactone | Post-Market | Hypertension |
| Cariprazine | Phase 3 | Major Depressive Disorder |
| RGB-14-P | Phase 3 | Postmenopausal Osteoporosis |
| Letrozole 5 mg | Phase 2 | IVF |
| RGH-896 | Phase 2 | Diabetic Peripheral Neuropathic Pain |
| Ulipristal acetate | Phase 2 | Adenomyosis |
| RGH-706 | Phase 2 | Prader-Willi Syndrome |
| Antidepressant + cariprazine (0.1-0.3 mg/day) | Phase 2 | Major Depressive Disorder |
| MabThera (rituximab) | Phase 1 | Rheumatoid Arthritis |
| RGB-10 | Phase 1 | Healthy |
| RGB-02 or Neulasta® (pegfilgrastim) | Phase 1 | Bioequivalence |
| Empagliflozin + Metformin hydrochloride 5 mg/1000 mg combination film-coated tablets | Phase 1 | Diabetes Mellitus Type 2 |
| Azilsartan medoxomil 80 mg tablet | Phase 1 | Hypertension |
| Cariprazine prolonged release tablet A | Phase 1 | Pharmacokinetic Profile |
Latest
No recent events.
Follow Gedeon Richter on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.